TriSalus Life Sciences (NASDAQ:TLSI) Announces Earnings Results, Beats Estimates By $0.01 EPS

TriSalus Life Sciences (NASDAQ:TLSI) announced its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01, Zacks reports. The firm had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• TriSalus reported strong results with Q4 revenue of $13.2M and full-year revenue of $45.2M (up 60% and 53% YoY) while improving gross margin and materially narrowing adjusted EBITDA loss, and it achieved its 2025 revenue guidance.
• The company completed a more-than-2x-oversubscribed public offering in February, raising $46 million in gross proceeds to fund commercial expansion, clinical evidence generation, and product innovation.
• Management is virtually doubling the commercial footprint and expanding the TriNav portfolio to seven offerings (including the anticipated H1 2026 launch of TriNav Advance), reaffirmed 2026 revenue guidance of $60–62M, and expects H2-weighted growth as new hires are onboarded and new products scale.
• The company delayed release of consolidated Phase 1 data for nelitolimod to H2 2026 to create a more complete data package for partners and has substantially reduced internal development spending, which could defer near-term partnership progress or value realization.

TriSalus Life Sciences Price Performance

Shares of TLSI traded down $0.63 on Friday, reaching $4.14. 172,981 shares of the stock traded hands, compared to its average volume of 159,014. The stock’s 50-day moving average price is $5.41 and its 200-day moving average price is $5.36. The firm has a market cap of $207.25 million, a price-to-earnings ratio of -2.05 and a beta of 0.42. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95.

TriSalus Life Sciences News Roundup

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Company reaffirmed 2026 revenue guidance of $60.0M–$62.0M and says it is expanding its PEDD commercial portfolio — this guidance sits well above street revenue consensus (~$54.1M) and supports upside to top-line expectations. TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
• Positive Sentiment: Company reported year-end and Q4 results and reiterated 2026 revenue guidance in its press release; management emphasized strong revenue growth and commercial momentum in the earnings commentary. TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
• Positive Sentiment: Lake Street reiterated its Buy rating on TLSI, a vote of confidence from a sell‑side firm that can support demand for the shares. Lake Street Sticks to Its Buy Rating for TriSalus Life Sciences (TLSI)
• Neutral Sentiment: Analyst/model updates: Northland Securities published FY2025 estimates for TLSI (useful for benchmark/consensus tracking), but no major change in consensus view was announced in the summary. Northland Securities Estimates TLSI FY2025 Earnings
• Neutral Sentiment: Full Q4 earnings call transcripts and highlights were posted (Seeking Alpha, Yahoo Finance) — useful for management tone and details on commercialization and margins but not new headline items beyond guidance and the quarter. TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Q4 EPS missed analyst expectations (reported -$0.21 vs. consensus -$0.13), which likely pressured the stock despite revenue meeting estimates ($13.21M vs. $13.20M). The EPS shortfall is a near‑term negative catalyst as investors digest profitability progress. TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently made changes to their positions in TLSI. Bank of America Corp DE increased its stake in TriSalus Life Sciences by 1.8% in the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock valued at $1,030,000 after acquiring an additional 3,374 shares during the period. Millennium Management LLC boosted its holdings in TriSalus Life Sciences by 17.7% during the third quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock valued at $166,000 after purchasing an additional 5,359 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $47,000. Finally, Invesco Ltd. acquired a new position in shares of TriSalus Life Sciences in the 4th quarter worth approximately $72,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TLSI. Canaccord Genuity Group boosted their price objective on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.